Active — Not RecruitingNot Applicable

A Study of Brigatinib as Preferred First Therapy for Adults With Non-Small Cell Lung Cancer (NSCLC) ENTIRETY

Poland50 participantsStarted 2023-05-22

Plain-language summary

This is a study of brigatinib in adults with Non-Small Cell Lung Cancer (NSCLC). The main aim of this study is to learn about the time period in which the condition does not worsen after the participant has received brigatinib. Another aim is to learn about the overall rate of participants who respond to the treatment with brigatinib. Participants will receive brigatinib as part of their normal clinical practice. Data will be collected during regular visits to the hospital (a total of up to 12 visits is planned throughout study duration).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Adult (aged ≥18) ALK positive NSCLC participants receiving brigatinib as a first-line treatment in the scope of NDP.
✓. Participants willing to participate in the study and signed ICF.

Exclusion criteria

✕. Current or planned participation in an interventional clinical trial for ALK positive non-small cell lung cancer (NSCLC).
✕. Cognitive incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.

What they're measuring

Real-World Progression Free Survival (rwPFS)

Timeframe: Up to 33 months

Trial details

NCT IDNCT05735327

SponsorTakeda

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2027-04-26

View on ClinicalTrials.gov More Non-small Cell Lung Cancer (NSCLC) trials